Ipsen ushers in new leadership to steer ANZ operations

Ipsen has appointed Dagmar Tschoep as General Manager for Australia & New Zealand, effective 1 October 2025. She succeeds Julien Dagher, who has relocated to Sweden to take on the role of General Manager for Ipsen across the Nordic and Baltic countries.

With more than two decades of experience in commercial and sales leadership, Tschoep brings a strong international background to the ANZ role. Since joining Ipsen in 2021 as Country Manager for Austria & Switzerland, she has delivered significant impact by expanding the organisation’s footprint and elevating business performance.

“I’m super excited to take over the leadership for the ANZ team and advance together our Ipsen portfolio – especially bringing the new launches to Australian patients,” Tschoep shared.

Her career spans senior leadership positions at Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Wyeth, and Interpharma, where she successfully drove product launches and championed innovation. Holding a Master’s in International Business Administration from the University of Vienna and an Executive MBA from Boston College & Management Centre Innsbruck, Tschoep is well-positioned to lead Ipsen ANZ through its next phase of growth.

Ipsen Australia is a mid-sized pharmaceutical company focused on oncology, rare diseases, and neurological disorders. Recent milestones include securing PBS listings for two important medicines: Sohonos (palovarotene) for Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic condition, and Soolantra (ivermectin) for rosacea.

At its July meeting, the PBAC also recommended reimbursement for Cabometyx in pancreatic and extra-pancreatic neuroendocrine tumors (pNET, epNET), as well as Bylvay for progressive familial intrahepatic cholestasis (PFIC).

“Tschoep will be relocating to Melbourne just in time to enjoy the warmer weather, and we couldn’t be more excited to welcome her to the region,” the company said in a statement.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.